Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 1011-1017, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nowak, I.
Right arrow Articles by Shaw, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nowak, I.
Right arrow Articles by Shaw, L. M.

Clinical Chemistry, Vol 41, 1011-1017, Copyright © 1995 by American Association for Clinical Chemistry

Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics

I Nowak and LM Shaw
Department of Pathology, University of Pennsylvania Medical Center, Philadelphia 19104, USA.

Mycophenolate mofetil, the prodrug form of the immunosuppressive agent mycophenolic acid (MPA), is currently in clinical trials evaluating its effectiveness in transplant recipients. In this study, we validated an ultrafiltration system for the reliable measurement of free MPA. Using this technique, we evaluated factors that might be important in modulating the free fraction of this drug. Human serum albumin (HSA), high concentrations of the primary glucuronide metabolite of MPA, and sodium salicylate significantly affected MPA binding. For HSA the mean +/- SE binding capacity (Bmax) and the dissociation constant (Kd) were 1095 +/- 34 mumol/L and 12.98 +/- 0.93 mumol/L, respectively. The dose for 50% inhibition (IC50) of inosine monophosphate dehydrogenase isoform II by MPA increased 5.4-fold as the concentration of HSA added to the enzyme reaction mixture increased from 0 to 50 g/L (0-724 mumol/L). Furthermore, the IC50 MPA concentration for phytohemagglutinin A-stimulated human peripheral blood mononuclear cells increased 4.8-fold when incubations were performed in the presence of 10 g/L (145 mumol/L) HSA vs no added HSA. These data support the hypothesis that the pharmacological activity of MPA is a function of unbound drug concentration.


The following articles in journals at HighWire Press have cited this article:


Home page
 CJASNHome page
H. Jeong and B. Kaplan
Therapeutic Monitoring of Mycophenolate Mofetil
Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 184 - 191.
[Full Text] [PDF]

Home page
 LupusHome page
A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco
Mycophenolate mofetil and systemic lupus erythematosus
Lupus, November 1, 2006; 15(11_suppl): 44 - 54.
[Abstract] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. M. van Hest, R. A.A. Mathot, M. D. Pescovitz, R. Gordon, R. D. Mamelok, and T. van Gelder
Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing: A Population Pharmacokinetic Meta-Analysis of Mycophenolic Acid in Renal Transplant Recipients
J. Am. Soc. Nephrol., March 1, 2006; 17(3): 871 - 880.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Giaccone, J. S. McCune, M. B. Maris, T. A. Gooley, B. M. Sandmaier, J. T. Slattery, S. Cole, R. A. Nash, R. F. Storb, and G. E. Georges
Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation
Blood, December 15, 2005; 106(13): 4381 - 4388.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
P. A. Jacobson, K. G. Green, and B. J. Hering
Mycophenolate Mofetil in Islet Cell Transplant: Variable Pharmacokinetics but Good Correlation Between Total and Unbound Concentrations
J. Clin. Pharmacol., August 1, 2005; 45(8): 901 - 909.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
O. J. Naderer, R. E. Dupuis, E. L. Heinzen, K. Wiwattanawongsa, M. W. Johnson, and P. C. Smith
The Influence of Norfloxacin and Metronidazole on the Disposition of Mycophenolate Mofetil
J. Clin. Pharmacol., February 1, 2005; 45(2): 219 - 226.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. Pisupati, A. Jain, G. Burckart, I. Hamad, S. Zuckerman, J. Fung, and R. Venkataramanan
Intraindividual and Interindividual Variations in the Pharmacokinetics of Mycophenolic Acid in Liver Transplant Patients
J. Clin. Pharmacol., January 1, 2005; 45(1): 34 - 41.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
E. K. Cho, D. J. Han, S. C. Kim, G. J. Burckart, R. Venkataramanan, and J. M. Oh
Pharmacokinetic Study of Mycophenolic Acid in Korean Kidney Transplant Patients
J. Clin. Pharmacol., July 1, 2004; 44(7): 743 - 750.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. Streit, M. Shipkova, V. W. Armstrong, and M. Oellerich
Validation of a Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Free and Total Mycophenolic Acid
Clin. Chem., January 1, 2004; 50(1): 152 - 159.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
T. M. Sievers
New Antiproliferative Immunosuppressive Agents
Journal of Pharmacy Practice, December 1, 2003; 16(6): 401 - 413.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
R. De Smet, J. Van Kaer, B. Van Vlem, A. De Cubber, P. Brunet, N. Lameire, and R. Vanholder
Toxicity of Free p-Cresol: A Prospective and Cross-Sectional Analysis
Clin. Chem., March 1, 2003; 49(3): 470 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. T. Weber, M. Shipkova, V. W. Armstrong, N. Wagner, E. Schutz, O. Mehls, L. B. Zimmerhackl, M. Oellerich, and B. Tonshoff
Comparison of the Emit Immunoassay with HPLC for Therapeutic Drug Monitoring of Mycophenolic Acid in Pediatric Renal-Transplant Recipients on Mycophenolate Mofetil Therapy
Clin. Chem., March 1, 2002; 48(3): 517 - 525.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
L. T. Weber, M. Shipkova, V. W. Armstrong, N. Wagner, E. Schuutz, O. Mehls, L. B. Zimmerhackl, M. Oellerich, and B. Tonshoff
The Pharmacokinetic-Pharmacodynamic Relationship for Total and Free Mycophenolic Acid in Pediatric Renal Transplant Recipients: A Report of the German Study Group on Mycophenolate Mofetil Therapy
J. Am. Soc. Nephrol., March 1, 2002; 13(3): 759 - 768.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. De Smet, J. Van Kaer, H. Liebich, G. Lesaffer, A. Verstraete, A. Dhondt, P. Duym, N. Lameire, and R. Vanholder
Heparin-induced Release of Protein-bound Solutes during Hemodialysis Is an in Vitro Artifact
Clin. Chem., May 1, 2001; 47(5): 901 - 909.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Mourad, J. Malaise, D. Chaib Eddour, M. De Meyer, J. Konig, R. Schepers, J. P. Squifflet, and P. Wallemacq
Correlation of Mycophenolic Acid Pharmacokinetic Parameters with Side Effects in Kidney Transplant Patients Treated with Mycophenolate Mofetil
Clin. Chem., January 1, 2001; 47(1): 88 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
O. Millan, F. Oppenheimer, M. Brunet, J. Vilardell, I. Rojo, J. Vives, and J. Martorell
Assessment of Mycophenolic Acid-induced Immunosuppression: A New Approach
Clin. Chem., September 1, 2000; 46(9): 1376 - 1383.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
F. A. De Wolf and G. M. Brett
Ligand-Binding Proteins: Their Potential for Application in Systems for Controlled Delivery and Uptake of Ligands
Pharmacol. Rev., June 1, 2000; 52(2): 207 - 236.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Vanholder, R. De Smet, and G. Lesaffer
p-Cresol: a toxin revealing many neglected but relevant aspects of uraemic toxicity
Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2813 - 2815.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. F. Gummert, M. J. Barten, S. W. Sherwood, T. van Gelder, and R. E. Morris
Pharmacodynamics of Immunosuppression by Mycophenolic Acid: Inhibition of Both Lymphocyte Proliferation and Activation Correlates with Pharmacokinetics
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1100 - 1112.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
M. Korecka, D. Nikolic, R. B. van Breemen, and L. M. Shaw
The Apparent Inhibition of Inosine Monophosphate Dehydrogenase by Mycophenolic Acid Glucuronide Is Attributable to the Presence of Trace Quantities of Mycophenolic Acid
Clin. Chem., July 1, 1999; 45(7): 1047 - 1050.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. F. GUMMERT, T. IKONEN, and R. E. MORRIS
Newer Immunosuppressive Drugs: A Review
J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1366 - 1380.
[Abstract] [Full Text]

Home page
 J. Am. Soc. Nephrol.Home page
M. A. DOOLEY, F. G. COSIO, P. H. NACHMAN, M. E. FALKENHAIN, S. L. HOGAN, R. J. FALK, and L. A. HEBERT
Mycophenolate Mofetil Therapy in Lupus Nephritis: ClinicalObservations
J. Am. Soc. Nephrol., April 1, 1999; 10(4): 833 - 839.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
M. Shipkova, P. D. Niedmann, V. W. Armstrong, E. Schutz, E. Wieland, L. M. Shaw, and M. Oellerich
Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure
Clin. Chem., July 1, 1998; 44(7): 1481 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. M. Shaw, B. Kaplan, and K. L. Brayman
Prospective investigations of concentration–clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring
Clin. Chem., February 1, 1998; 44(2): 381 - 387.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Griesmacher, G. Weigel, G. Seebacher, and M. M. Muller
IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide
Clin. Chem., December 1, 1997; 43(12): 2312 - 2317.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.